Alvotech Secures Additional $75M Term Loan Facility from GoldenTree
ALVO sits 29% above its 52-week low of $2.94.
Summary
Alvotech has secured an additional $75 million term loan facility from GoldenTree Asset Management, further strengthening its liquidity following a recent $165 million equity raise.
Key Events · Financing and Capital Events · ALVO
-
Secured $75 Million Term Loan
Alvotech obtained an additional $75 million term loan facility from GoldenTree Asset Management, maturing December 31, 2027.
-
High Interest Rate
The new loan carries a 12.50% interest rate, payable monthly in cash.
-
Enhanced Liquidity
This financing follows a recent $165 million equity raise, bringing the total new capital access to $240 million.
-
Strategic Funding
Funds will support the company's R&D pipeline and global product launches, reinforcing its growth strategy.
Analysis · ALVO · Life Sciences
This financing provides Alvotech with crucial capital to advance its biosimilar pipeline and support global product launches. While the 12.50% interest rate is high, securing these funds is vital for the company's operational runway, especially after a series of recent capital raises. The total new capital access, including the prior equity raise, now stands at $240 million, significantly bolstering liquidity.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 962 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALVO was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.94 to $9.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.